The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I
or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R1, R2 and Y are as described herein.
本发明涉及可用作苹果酸酶(ME)抑制剂的新型化合物、其制备工艺以及这些化合物用于治疗由ME介导的疾病,如人类癌症(如胰腺导管腺癌(PDAC))。这些新型化合物具有符合式 I 的结构
或其药学上可接受的盐、立体异构体或氚代类似物,其中 X、R1、R2 和 Y 如本文所述。
[EN] ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR<br/>[FR] COMPOSES CHIMIQUES
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2005016867A3
公开(公告)日:2005-03-31
MALIC ENZYME INHIBITORS
申请人:SUN PHARMA ADVANCED RESEARCH COMPANY LTD
公开号:US20210115038A1
公开(公告)日:2021-04-22
The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.
The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans.